Allakos Appoints Steven P. James to Board of Directors
SAN CARLOS, CA (November 3, 2016): Allakos today announced the appointment of Steven P. James to the Allakos Board of Directors. Mr. James is also Executive Chairman and Chief Executive Officer of Precision Immune, Inc., and was the President, CEO, and Director of Labrys Biologics, Inc. from December 2012 until it was acquired by Teva Pharmaceuticals in July 2014.
"Steve has a demonstrated track record of value creation in biotechnology, and we are excited to have him join Allakos as an independent director," said Christopher Bebbington, DPhil., Allakos President and CEO. "Steve’s knowledge and experience will serve Allakos well as our company enters its next stage of growth."
"I am honored to join the board of Allakos," commented Mr. James. "Allakos has a first-rate team, top investors, and a promising pipeline of first-in-class antibodies which address serious and underserved diseases."
Steve James has 25 years of life sciences experience and has been involved in the formation and management of numerous biotechnology companies. Prior to joining Labrys, Steve was President, CEO and Director of KAI Pharmaceuticals, Inc. from October 2004 until the company was acquired by Amgen in July 2012. His previous positions have included Senior Vice President of Commercial Operations at Exelixis; Chief Business Officer at Sunesis Pharmaceuticals and VP of Business Development at Isis Pharmaceuticals (now Ionis). He began his career in new product planning at Eli Lilly. He holds a Masters in Management from the Kellogg School of Northwestern University and an undergraduate degree from Brown University. Steve is Chairman of Antiva Biosciences, and a director of Ocera Therapeutics, Chrono Therapeutics, and Cascadian Therapeutics (formerly, Oncothyrean, Inc).
Allakos, a privately held clinical stage biotechnology company, is a scientific leader the field of mast cell biology, focused on the central role these immune system cells play in the pathology of severe inflammatory, fibrotic and proliferative diseases. The company is developing therapeutic antibodies that target a key receptor, Siglec-8, on the surface of mast cells and eosinophils and selectively inhibit the cells’ activity or deplete them from tissues. Antibodies against Siglec-8 offer potential for the development of a broad range of proprietary first-in-class treatments for both serious illnesses affecting large patient populations and rare diseases for which no effective treatments exist. The company currently has two drug candidates in clinical development. AK001 is in a Phase 2 trial for patients with moderate to severe nasal polyposis (with or without asthma). AK002 is in Phase 1 trials in healthy volunteers and in patients with systemic mastocytosis. The company also has a third program focused on development of antibodies that target a novel checkpoint inhibitor for immuno-oncology applications. For further information, please visit www.Allakos.com.
Chief Business Officer
T: 650 597 5002
Nicole Litchfield, email@example.com
Joan Kureczka, firstname.lastname@example.org